CASI Pharmaceuticals, Inc.

NasdaqCM:CASI Stock Report

Market Cap: US$39.9m

CASI Pharmaceuticals Future Growth

Future criteria checks 2/6

CASI Pharmaceuticals is forecast to grow earnings and revenue by 9% and 35.9% per annum respectively while EPS is expected to grow by 12.9% per annum.

Key information

9.0%

Earnings growth rate

12.9%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate35.9%
Future return on equityn/a
Analyst coverage

Low

Last updated15 May 2024

Recent future growth updates

Recent updates

The Market Doesn't Like What It Sees From CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues Yet As Shares Tumble 34%

Nov 26
The Market Doesn't Like What It Sees From CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues Yet As Shares Tumble 34%

CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

May 21
CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%

Mar 12
Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%

Dec 18
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%

We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate

Sep 02
We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?

May 20
Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?

Casi to sell stake in Juventas to Jiadao Gongcheng for ~RMB240.87M

Sep 23

CASI Pharmaceuticals Q2 2022 Earnings Preview

Aug 11

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

May 26
Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts

Aug 14
Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts

Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?

May 25
Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?

Earnings and Revenue Growth Forecasts

NasdaqCM:CASI - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202670-28N/AN/A1
12/31/202546-33N/AN/A1
12/31/202420-36N/AN/A1
9/30/202422-31N/AN/AN/A
6/30/202423-27N/AN/AN/A
3/31/202429-30N/AN/AN/A
12/31/202334-27-22-20N/A
9/30/202342-40N/AN/AN/A
6/30/202344-41N/AN/AN/A
3/31/202342-38N/AN/AN/A
12/31/202243-41-27-21N/A
9/30/202237-27-35-28N/A
6/30/202235-32-35-25N/A
3/31/202233-31-34-23N/A
12/31/202130-37-42-27N/A
9/30/202126-45-44-27N/A
6/30/202122-52-54-30N/A
3/31/202117-54-53-29N/A
12/31/202015-48-43-26N/A
9/30/202012-47-41-23N/A
6/30/202010-40-29-21N/A
3/31/20208-46-36-23N/A
12/31/20194-46-37-23N/A
9/30/20193-43-42-34N/A
6/30/2019N/A-42-42-33N/A
3/31/2019N/A-32-31-28N/A
12/31/2018N/A-27-50-29N/A
9/30/2018N/A-23-35-15N/A
6/30/2018N/A-16N/A-12N/A
3/31/2018N/A-13N/A-11N/A
12/31/2017N/A-11N/A-6N/A
9/30/2017N/A-8N/A-7N/A
6/30/2017N/A-8N/A-7N/A
3/31/2017N/A-9N/A-6N/A
12/31/2016N/A-9N/A-6N/A
9/30/2016N/A-8N/A-6N/A
6/30/2016N/A-8N/A-6N/A
3/31/20160-7N/A-6N/A
12/31/20150-7N/A-6N/A
9/30/20150-7N/A-5N/A
6/30/20150-27N/A-5N/A
3/31/20150-27N/A-4N/A
12/31/20140-26N/A-4N/A
9/30/2014N/A-26N/A-4N/A
6/30/2014N/A-6N/A-4N/A
3/31/2014N/A-6N/A-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CASI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CASI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CASI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CASI's revenue (35.9% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: CASI's revenue (35.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CASI's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 07:58
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CASI Pharmaceuticals, Inc. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Justin ZelinBTIG
Nathaniel CallowayEdison Investment Research
Ching-Yi LinH.C. Wainwright & Co.